Drug-eluting Balloon Catheters Market Size

The global drug-eluting balloon catheters market size was valued at USD 637.8 million in 2024 and is expected to exhibit growth at a CAGR of 9.9% from 2025 to 2034. High market growth can be attributed to the growing prevalence of peripheral and cardiovascular diseases, an increasing preference for minimally invasive procedures, and a rising geriatric population, among other contributing factors.

The incidence of cardiovascular diseases (CVDs), including coronary artery disease, strokes, and peripheral artery disease (PAD), has surged globally due to risk factors such as aging, unhealthy lifestyles, and the prevalence of conditions like diabetes and hypertension. For instance, according to the Centers for Disease Control and Prevention (CDC), cardiovascular diseases remain the leading cause of death globally, with an estimated 19 million deaths in 2021.

In the U.S. alone, heart disease accounted for 702,880 deaths in 2022, which is about one in every five deaths. This rising incidence has intensified the demand for minimally invasive treatments, where drug-eluting balloon (DEB) catheters have a distinct advantage in reducing arterial blockages and improving blood flow without leaving a permanent implant. DEBs are particularly effective in treating complex lesions where traditional stents may be less effective, further driving their adoption.

Drug-eluting balloon catheters, also known as drug-coated balloons, aid in treating hyperplasia. The catheter carries an antiproliferative drug, usually paclitaxel or sirolimus, which is delivered to the arterial walls as the balloon expands. Additionally, it offers controlled drug delivery to treat cardiovascular or peripheral diseases.